News

SCOHIA initites a Phase 1 Multiple-Dose Clinical Trial for SCO-240

Publication of a clinical phase 1 study of SCO-240: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders

S-483, a Pre-clinical Program for 21-Hydroxylase Deficiency, Was Selected as a Support Program of AMED

SCO-240, a Clinical Program for Pediatric Growth Hormone Deficiency, Was Selected as a Support Program of AMED

Presentation of clinical data of SCO-240 at the 96^th annual congress of Japan Endocrine Society: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders

SCOHIA PHARMA and Huadong Announce Global Expansion of the Strategic Collaboration for SCO-094

Issuance of Key Patent Covering Novel Nrf2 Activator

Publication of a clinical phase 2 study of SCO-792

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator

Publication of medicinal chemistry research on SCO-792, an enteropeptidase inhibitor